Stock info BioCorRx Inc | Filter  Basic-Info

Stock: BioCorRx Inc (US broad)

Last Price 0.40 Max Price 0.50
Min Price 0.06 1 Year return -72.97
Sector Health Care Subsector Health Care Eq. & Services

Loading...

Contact info:Country: USA

Sector Review BioCorRx Inc

Loading...
Year Turnover Total sector Market share
2019 0 1,914,856 0.00 %
2020 0 1,909,941 0.00 %
2021 0 2,244,427 0.00 %
2022 0 2,638,646 0.00 %
2023 0 2,748,111 0.00 %

Advice BioCorRx Inc

No Records Found



News BioCorRx Inc

No Records Found

Annual reports BioCorRx Inc

No Records Found

Profile BioCorRx Inc

No Records Found

Results BioCorRx Inc

Results
2021
2022
2023
2024
2025
Revenue
Costs
Profit
Margin of profit
ROI

Balance BioCorRx Inc

Balance
2021
2022
2023
2024
2025
Equity
Debt
Total assets
Solvency
Cash
Cashflow
Employees
Revenue per employee
Cashflow / Debt

Details BioCorRx Inc

Details
2016
2017
2018
2019
2020
Price
3.00
16.59
5.48
2.75
0.95
Eps
-3.30
-10.64
-2.27
-1.53
-0.53
Price/earnings-ratio
-0.91
-1.56
-2.41
-1.80
-0.75
Dividend
0.0
0.0
0.0
0.0
Dividend %
0.00 %
0.00 %
0.00 %
0.00 %
Payout %
0.0
0.0
0.0
0.0
Book value
-4.25
-1.33
-1.89
-0.16
-0.61
Market to book
-1.42
-0.08
-0.34
-0.06
-1.53
Cashflow per stock
-1.04
-0.87
-0.61
-0.49
-0.32
Stocks
2
2
3
5
5
Market Cap
5.45
40.49
14.23
14.65
2.19

Dividend BioCorRx Inc

Price info BioCorRx Inc

Date
Price
19 Mar 2026
0.40
17 Mar 2026
0.40
10 Mar 2026
0.40
08 Mar 2026
0.26
03 Mar 2026
0.30
24 Feb 2026
0.35
10 Feb 2026
0.26
06 Feb 2026
0.26
04 Feb 2026
0.30
28 Jan 2026
0.06
26 Jan 2026
0.40
21 Jan 2026
0.40
17 Jan 2026
0.40
13 Jan 2026
0.29
21 Dec 2025
0.40
18 Dec 2025
0.35
17 Dec 2025
0.34
16 Dec 2025
0.38
15 Dec 2025
0.38
11 Dec 2025
0.39
10 Dec 2025
0.33
09 Dec 2025
0.35
04 Dec 2025
0.35
03 Dec 2025
0.33
27 Nov 2025
0.33
26 Nov 2025
0.33
22 Nov 2025
0.40
20 Nov 2025
0.28
19 Nov 2025
0.44
18 Nov 2025
0.45
Overig aandelennieuws
BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
BioCorRx Reports Business Update for the Third Quarter of 2023
BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
BioCorRx Reports Business Update for the Second Quarter of 2023
BioCorRx Announced Interim Positive Safety and Pharmacokinetic Results of Phase 1 Clinical Trial at 4th Annual NIH HEAL Initiative Investigator Meeting
BioCorRx Attended 4th Annual NIH HEAL Initiative Investigator Meeting; Shares Update on BICX104 Data
Analist
Returns European stocks
Crypto currencies information
About us Network Partners
Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x
    ©2026 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo